Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Larry Ramer

Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Novo Nordisk (NVO) has multiple positive catalysts on the horzon, including its recent decision to offer subscriptions to Wegovy, its popular GLP-1 weight-loss drug. Still, given a forthcoming — and potentially huge — negative catalyst facing the company, investors may want to refrain from buying NVO stock for now.

What's going on with Novo Nordisk? Let's take a closer look.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.